Barclays analyst Gena Wang downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Equalweight to Underweight with a price target of $10.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE